Private Market View

Tianfeng Biotechnology

Shenyang, China · Founded 2005 · Privately Held (backing)

Last price · $/share
Implied valuation
Total raised
Last round

Key facts

  • Notable investors include Shenyang Information Industry Venture Capital, Zhongtian Liaochuang Investment.
  • Status: Privately Held (backing).
Free account
See the evidence behind this price
  • ·The complete investor list — 2 names
  • ·Watchlist + deal alerts for Tianfeng Biotechnology
  • ·The full record, as it builds
Create free account
No card required

Funding rounds

No rounds on record

No funding rounds for Tianfeng Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

About Tianfeng Biotechnology

Manufacturer of pharmaceuticals intended for therapeutic and clinical treatment purposes. The company offers research and development of active compounds, standardized production processes, quality assurance systems, regulatory compliance, and distribution channels for medical use, enabling healthcare markets to access consistent therapeutic agents, support patient care, maintain treatment reliability, and achieve broad application across oncology, infectious disease, and other specialized medical fields through controlled and scalable biopharmaceutical solutions.

Sector
Healthcare
HQ
Shenyang, China
Founded
2005
Employees
28
Ownership
Privately Held (backing)
PA Mark — not yet priced

Tianfeng Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.

Pro members can request priority coverage with a 48-hour turnaround.

Recorded secondary trades

No prints on record

No secondary trades in Tianfeng Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.

Pro members can request priority coverage with a 48-hour turnaround.

Institutional fund marks

No fund marks yet

No SEC-registered fund has reported a fair-value mark on Tianfeng Biotechnology in its N-PORT filings yet. We sweep new filings monthly.

Pro members can request priority coverage with a 48-hour turnaround.